These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 10979978)

  • 1. Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex.
    Shiotsu Y; Neckers LM; Wortman I; An WG; Schulte TW; Soga S; Murakata C; Tamaoki T; Akinaga S
    Blood; 2000 Sep; 96(6):2284-91. PubMed ID: 10979978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts.
    Nimmanapalli R; O'Bryan E; Bhalla K
    Cancer Res; 2001 Mar; 61(5):1799-804. PubMed ID: 11280726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules.
    Soga S; Neckers LM; Schulte TW; Shiotsu Y; Akasaka K; Narumi H; Agatsuma T; Ikuina Y; Murakata C; Tamaoki T; Akinaga S
    Cancer Res; 1999 Jun; 59(12):2931-8. PubMed ID: 10383157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radicicol-mediated inhibition of Bcr-Abl in K562 cells induced p38-MAPK dependent erythroid differentiation and PU.1 down-regulation.
    Morceau F; Buck I; Dicato M; Diederich M
    Biofactors; 2008; 34(4):313-29. PubMed ID: 19850986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
    George P; Bali P; Annavarapu S; Scuto A; Fiskus W; Guo F; Sigua C; Sondarva G; Moscinski L; Atadja P; Bhalla K
    Blood; 2005 Feb; 105(4):1768-76. PubMed ID: 15514006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereospecific antitumor activity of radicicol oxime derivatives.
    Soga S; Sharma SV; Shiotsu Y; Shimizu M; Tahara H; Yamaguchi K; Ikuina Y; Murakata C; Tamaoki T; Kurebayashi J; Schulte TW; Neckers LM; Akinaga S
    Cancer Chemother Pharmacol; 2001 Dec; 48(6):435-45. PubMed ID: 11800023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin.
    Wu LX; Xu JH; Zhang KZ; Lin Q; Huang XW; Wen CX; Chen YZ
    Leukemia; 2008 Jul; 22(7):1402-9. PubMed ID: 18418407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The mechanism of apoptosis of chronic myeloid leukemia cells induced by the novel p210 bcr/abl inhibitor berbamine].
    Sun JR; Zhang XH; He ZW; Gu Y; Yu YZ; Fang YM; Lü QH; Dong QH; Xu RZ
    Zhonghua Yi Xue Za Zhi; 2006 Aug; 86(32):2246-51. PubMed ID: 17064567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of herbimycin A and its derivatives on growth and differentiation of Ph1-positive acute lymphoid leukemia cell lines.
    Sato S; Honma Y; Hozumi M; Hayashi Y; Matsuo Y; Shibata K; Omura S; Hino K; Tomoyasu S; Tsuruoka N
    Leuk Res; 1994 Mar; 18(3):221-8. PubMed ID: 8139288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth.
    Okabe M; Uehara Y; Miyagishima T; Itaya T; Tanaka M; Kuni-Eda Y; Kurosawa M; Miyazaki T
    Blood; 1992 Sep; 80(5):1330-8. PubMed ID: 1515646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of p210(bcr/abl) by curcumin involves disrupting molecular chaperone functions of Hsp90.
    Wu LX; Xu JH; Huang XW; Zhang KZ; Wen CX; Chen YZ
    Acta Pharmacol Sin; 2006 Jun; 27(6):694-9. PubMed ID: 16723087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome.
    An WG; Schulte TW; Neckers LM
    Cell Growth Differ; 2000 Jul; 11(7):355-60. PubMed ID: 10939589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of radicicol analogues.
    Soga S; Shiotsu Y; Akinaga S; Sharma SV
    Curr Cancer Drug Targets; 2003 Oct; 3(5):359-69. PubMed ID: 14529387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin.
    Schulte TW; Akinaga S; Soga S; Sullivan W; Stensgard B; Toft D; Neckers LM
    Cell Stress Chaperones; 1998 Jun; 3(2):100-8. PubMed ID: 9672245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
    Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
    Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCR/ABL oncoprotein-targeted antitumor activity of antisense oligodeoxynucleotides complementary to bcr/abl mRNA and herbimycin A, an antagonist of protein tyrosine kinase: inhibitory effects on in vitro growth of Ph1-positive leukemia cells and BCR/ABL oncoprotein-associated transformed cells.
    Okabe M; Kunieda Y; Miyagishima T; Kobayashi M; Kurosawa M; Itaya T; Sakurada K; Miyazaki T
    Leuk Lymphoma; 1993 Jul; 10(4-5):307-16. PubMed ID: 7693103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivation of ERK accelerates erythroid differentiation of K562 cells induced by herbimycin A and STI571 while activation of MEK1 interferes with it.
    Kawano T; Horiguchi-Yamada J; Iwase S; Furukawa Y; Kano Y; Yamada H
    Mol Cell Biochem; 2004 Mar; 258(1-2):25-33. PubMed ID: 15030167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hsp90 N- and C-terminal double inhibition synergistically suppresses Bcr-Abl-positive human leukemia cells.
    Chen C; Zhuang Y; Chen X; Chen X; Li D; Fan Y; Xu J; Chen Y; Wu L
    Oncotarget; 2017 Feb; 8(6):10025-10036. PubMed ID: 28036294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of erythroid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity.
    Honma Y; Okabe-Kado J; Hozumi M; Uehara Y; Mizuno S
    Cancer Res; 1989 Jan; 49(2):331-4. PubMed ID: 2910452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resveratrol induces apoptosis in K562 (chronic myelogenous leukemia) cells by targeting a key survival protein, heat shock protein 70.
    Chakraborty PK; Mustafi SB; Ganguly S; Chatterjee M; Raha S
    Cancer Sci; 2008 Jun; 99(6):1109-16. PubMed ID: 18429957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.